FHLC: Why Patience Matters More Than Precision [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
FHLC's market-cap weighting enables dynamic exposure, reducing biotech risk in downturns and capturing upside in rallies, outperforming pure biotech or pharma over a decade. Currently, FHLC is highly concentrated in pharma, with Eli Lilly and Company at ~13%, which enhances near-term resilience but increases drawdown risk if heavyweights underperform. I rate FHLC a Hold for the near term due to biotech headwinds but a Buy for patient investors with a 10+ year horizon. Ivan Pantic/E+ via Getty Images For long-term investors, the Fidelity MSCI Health Care Index ETF ( FHLC ) remains a patient growth vehicle within healthcare, given the secular tailwinds of aging demographics, the GLP-1 addressable market, and biotech-led breakthrough treatments. However, that long term could This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients [Yahoo! Finance]Yahoo! Finance
- Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's weight-loss challenge in five charts [Yahoo! Finance]Yahoo! Finance
- Novo's Wegovy pill to test demand from consumers with cash [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo's Wegovy pill to test demand from consumers with cash [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website